MindRank Announces First-in-Human Phase 1 Study of MDR-001 in China

Clinical stage AI drug discovery company, MindRank, has announced the start of its first-in-human (FIH) Phase 1 study of MDR-001 in China. The proprietary glucagon-like peptide 1 receptor agonist (GLP-1 RA), which is an oral small-molecule designed to treat obesity and type 2 diabetes mellitus (T2DM), was discovered using MindRank's Molecule Pro AI platform. The FIH Phase 1 trial will evaluate t..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 15.
  • textsms

BIOTRONIK Announces First Implant of New Implantable Cardiac Monitor with Artificial Intelligence

BIOTRONIK, a global medical technology company specializing in cardiovascular, endovascular and neuromodulation solutions, has announced the first implantation of its BIOMONITOR IV implantable cardiac monitor (ICM) with artificial intelligence (AI). The device pairs SmartECG technology with AI to reduce false positive detections by 86%, while preserving 98% of true episodes. It is also capable o..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 13.
  • textsms

Iktos and Curreio Announce Collaboration Agreement in New Drug Discovery

French AI company Iktos and Japanese firm Curreio have announced a collaboration agreement in the field of new drug discovery, combining generative design technology with cryo-electron microscopy platform to speed up and reduce costs associated with preclinical drug candidate creation for an undisclosed target. Under the agreement, Iktos’ Makya generative AI technology will be used alongside str..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 9.
  • textsms